

# Eye Center South surgeon Dr. Sebastian Heersink 1st in Alabama to perform iDose® TR

*iDose TR helps patients with glaucoma take long-term control of high eye pressure*

DOTHAN, ALABAMA, UNITED STATES, May 17, 2024 /EINPresswire.com/ -- [Eye Center South](#), is proud to announce the availability of iDose® TR (travoprost intraocular implant) 75 mcg. iDose

“

We are excited to offer our patients this new treatment option, especially those who have difficulty using daily eye drops for their glaucoma.”

*Dr. Sebastian Heersink, Eye Center South*

TR is a new, FDA approved treatment that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with open-angle glaucoma or ocular hypertension. Dr. Sebastian Heersink was the first surgeon in the State of Alabama and throughout the Florida panhandle to perform this new outpatient procedure at Surgery Center South.

Dr. Heersink shared, “We are excited to offer our patients this new treatment option, especially those who have

difficulty using daily eye drops for their glaucoma. The recent announcement that it was FDA approved is a culmination of several years of diligent work to innovate and provide a cutting-edge treatment option to patients in the Wiregrass and around the country. This is a safe and effective treatment option for patients, and I am honored that we have played a role in bringing it to patients in Alabama and the Wiregrass.”

Glaucoma is an eye disease caused by increased pressure in the eye and it can also cause damage to the optic nerve which carries visual information from the eyes to the brain. If left untreated, glaucoma can cause permanent damage to the eye, which means vision loss cannot be reversed. Prescription eye drops are the most common treatment for glaucoma, but they can be difficult to administer correctly and can cause uncomfortable or irritating side effects for most patients. High rates of non-compliance and non-adherence to prescription medications contribute to disease progression.

“With iDose TR, we offer another option besides the standard practice of relying on daily drops, which may cause unpleasant side effects and be challenging to properly administer multiple

times a day,” said Dr. Sebastian Heersink, “By delivering an effective therapy directly inside of the eye, iDose TR is an alternative to prescription eye drops and a hands-free way to keep eye pressure under control.”

Developed by Glaukos, iDose TR reduces high or elevated pressure within the eye by automatically releasing the same type of medication used for decades in the most commonly prescribed eye drops. During a clinical study, 8 out of 10 patients did not need prescription eye drops 12 months after administration of iDose TR. iDose TR may be particularly beneficial for patients who have difficulty adhering to a daily medication regimen or whose condition is uncontrolled on topical glaucoma medications.

“Eye Center South is committed to providing our patients with the most advanced treatment options available,” said Tennille Finch, Senior Administrator. “iDose TR represents a significant development in how we can proactively address glaucoma care, and we are proud to be the first practice in Alabama to make this therapy available.”

For more information about iDose TR or to schedule an appointment, please visit our website at <https://www.eyecentersouth.net/specialties/glaucoma/idosetr/> or call us at 1-800-New-Eyes.

#### About Eye Center South

Established in 1980 in Dothan, Alabama, Eye Center South has built a steadfast reputation across the Southeast for delivering top-tier specialty eyecare. Our seasoned team of eye surgeons employs cutting-edge technology to administer advanced treatment for various eye conditions such as Cataracts, Glaucoma, Pediatric Strabismus, LASIK and Retina care. With several offices strategically located in central and south Alabama, as well as Northwest Florida, we ensure convenient access to dependable, centralized, and superior eyecare services.

#### IMPORTANT SAFETY INFORMATION

iDose TR is gently placed directly inside your eye by your eye doctor. You should not have iDose TR if you have an infection or suspected infection in your eye or the area surrounding your eye, have corneal endothelial cell dystrophy, a condition in which the clear front layer of your eye (cornea) has lost its ability to work normally as this can cause vision problems, have had a corneal transplant or cells transplanted to the inner layer of the cornea (endothelial cell transplant), are allergic to any of its ingredients, and /or have narrow angles (the iris and the



Dr. Sebastian Heersink, Eye Center South

cornea are too close together).

The most common side effect of iDose TR was increased eye pressure. Other common side effects were inflammation of the iris, dry eye, a loss of part of the usual field of vision, eye pain, eye redness and reduced clearness of vision. If you have additional questions, please contact your doctor. For full Prescribing Information visit [www.idosetr.com](http://www.idosetr.com).

#### APPROVED USES

iDose TR (travoprost intracameral implant) is a prescription medicine and drug delivery system for the eye approved to lower eye pressure in patients with open-angle glaucoma or high eye pressure (ocular hypertension). You are encouraged to report all side effects to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call 1-800-FDA-1088. You may also call Glaukos at 1-888-404-1644.

Kim Smith

Eye Center South

+1 334-798-5712

[email us here](#)

Visit us on social media:

[Facebook](#)

[Instagram](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/712429422>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.